Bristol-Myers Squibb Reports Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Bristol-Myers Squibb Co. (BMY) PT Lowered to $61 at Leerink Partners
July 28, 2017 10:31 AM EDTLeerink Partners lowered its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $61.00 (from $66.00) while maintaining a Outperform rating following the company's 2Q. BMY delivered in line earnings of 74c.
Analyst Seamus Fernandez now forecasts a 9% EPS growth in 2018-22E excluding Opdivo +... More
Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance
July 27, 2017 7:01 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $0.74, in-line with the analyst estimate of $0.74. Revenue for the quarter came in at $5.14 billion versus the consensus estimate of $5.09 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2017 EPS of $2.90-$3.00, versus the consensus of... More
